Cargando…

Add-On Effect of Selenium and Vitamin D Combined Supplementation in Early Control of Graves’ Disease Hyperthyroidism During Methimazole Treatment

Prompt and stable control of hyperthyroidism is fundamental to avoid the detrimental effects of thyroid hormone excess, and antithyroid drugs, mainly methimazole (MMI), represent the first-line treatment for Graves’ disease (GD) hyperthyroidism. Decreased serum concentrations of selenium (Se) and ca...

Descripción completa

Detalles Bibliográficos
Autores principales: Gallo, Daniela, Mortara, Lorenzo, Veronesi, Giovanni, Cattaneo, Simona AM, Genoni, Angelo, Gallazzi, Matteo, Peruzzo, Carlo, Lasalvia, Paolo, Moretto, Paola, Bruno, Antonino, Passi, Alberto, Pini, Andrea, Nauti, Andrea, Lavizzari, Maria Antonietta, Marinò, Michele, Lanzolla, Giulia, Tanda, Maria Laura, Bartalena, Luigi, Piantanida, Eliana
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9240752/
https://www.ncbi.nlm.nih.gov/pubmed/35784564
http://dx.doi.org/10.3389/fendo.2022.886451
_version_ 1784737637891833856
author Gallo, Daniela
Mortara, Lorenzo
Veronesi, Giovanni
Cattaneo, Simona AM
Genoni, Angelo
Gallazzi, Matteo
Peruzzo, Carlo
Lasalvia, Paolo
Moretto, Paola
Bruno, Antonino
Passi, Alberto
Pini, Andrea
Nauti, Andrea
Lavizzari, Maria Antonietta
Marinò, Michele
Lanzolla, Giulia
Tanda, Maria Laura
Bartalena, Luigi
Piantanida, Eliana
author_facet Gallo, Daniela
Mortara, Lorenzo
Veronesi, Giovanni
Cattaneo, Simona AM
Genoni, Angelo
Gallazzi, Matteo
Peruzzo, Carlo
Lasalvia, Paolo
Moretto, Paola
Bruno, Antonino
Passi, Alberto
Pini, Andrea
Nauti, Andrea
Lavizzari, Maria Antonietta
Marinò, Michele
Lanzolla, Giulia
Tanda, Maria Laura
Bartalena, Luigi
Piantanida, Eliana
author_sort Gallo, Daniela
collection PubMed
description Prompt and stable control of hyperthyroidism is fundamental to avoid the detrimental effects of thyroid hormone excess, and antithyroid drugs, mainly methimazole (MMI), represent the first-line treatment for Graves’ disease (GD) hyperthyroidism. Decreased serum concentrations of selenium (Se) and calcifediol (25(OH)D, VitD) have been reported in newly diagnosed GD patients in observational studies. Low Se levels might exacerbate oxidative stress by compromising the antioxidant machinery’s response to reactive oxygen species, and low VitD levels might hamper the anti-inflammatory immune response. We performed a randomized controlled clinical trial (EudraCT 2017-00505011) to investigate whether Se and cholecalciferol (VitD) addition to MMI is associated with a prompter control of hyperthyroidism. Forty-two consecutive patients with newly-onset GD and marginal/insufficient Se and VitD levels were randomly assigned to treatment with either MMI monotherapy or MMI combined with Se and VitD. Se treatment was withdrawn after 180 days, while the other treatments were continued. Combination therapy resulted in a significantly greater reduction in serum FT4 concentration at 45 days (-37.9 pg/ml, CI 95%, -43.7 to -32.2 pg/ml) and 180 days (-36.5 pg/ml, CI 95%, -42 to -30.9 pg/ml) compared to MMI monotherapy (respectively: -25.7 pg/ml, CI 95%, -31.6 to -19.7 pg/ml and -22.9 pg/ml, CI 95%, -28 to -17.3 pg/ml, p 0.002). Data at 270 days confirmed this trend (-37.8 pg/ml, CI 95%, -43.6 to -32.1 pg/ml vs -24.4 pg/ml, CI 95%, -30.3 to -18.4 pg/ml). The quality of life (QoL) score was investigated by the validated “Thyroid-related Patient-Reported Outcome” questionnaire (ThyPRO). ThyPRO composite score showed a greater improvement in the intervention group at 45 days (-14.6, CI 95%, -18.8 to -10.4), 180 (-9, CI 95%, -13.9 to -4.2) and 270 days (-14.3, CI 95%, -19.5 to -9.1) compared to MMI group (respectively, -5.2, CI 95%, -9.5 to -1; -5.4, CI 95%, -10.6 to -0.2 and -3.5, CI 95%, -9 to -2.1, p 0-6 months and 6-9 months <0.05). Our results suggest that reaching optimal Se and VitD levels increases the early efficacy of MMI treatment when Se and VitD levels are suboptimal.
format Online
Article
Text
id pubmed-9240752
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-92407522022-06-30 Add-On Effect of Selenium and Vitamin D Combined Supplementation in Early Control of Graves’ Disease Hyperthyroidism During Methimazole Treatment Gallo, Daniela Mortara, Lorenzo Veronesi, Giovanni Cattaneo, Simona AM Genoni, Angelo Gallazzi, Matteo Peruzzo, Carlo Lasalvia, Paolo Moretto, Paola Bruno, Antonino Passi, Alberto Pini, Andrea Nauti, Andrea Lavizzari, Maria Antonietta Marinò, Michele Lanzolla, Giulia Tanda, Maria Laura Bartalena, Luigi Piantanida, Eliana Front Endocrinol (Lausanne) Endocrinology Prompt and stable control of hyperthyroidism is fundamental to avoid the detrimental effects of thyroid hormone excess, and antithyroid drugs, mainly methimazole (MMI), represent the first-line treatment for Graves’ disease (GD) hyperthyroidism. Decreased serum concentrations of selenium (Se) and calcifediol (25(OH)D, VitD) have been reported in newly diagnosed GD patients in observational studies. Low Se levels might exacerbate oxidative stress by compromising the antioxidant machinery’s response to reactive oxygen species, and low VitD levels might hamper the anti-inflammatory immune response. We performed a randomized controlled clinical trial (EudraCT 2017-00505011) to investigate whether Se and cholecalciferol (VitD) addition to MMI is associated with a prompter control of hyperthyroidism. Forty-two consecutive patients with newly-onset GD and marginal/insufficient Se and VitD levels were randomly assigned to treatment with either MMI monotherapy or MMI combined with Se and VitD. Se treatment was withdrawn after 180 days, while the other treatments were continued. Combination therapy resulted in a significantly greater reduction in serum FT4 concentration at 45 days (-37.9 pg/ml, CI 95%, -43.7 to -32.2 pg/ml) and 180 days (-36.5 pg/ml, CI 95%, -42 to -30.9 pg/ml) compared to MMI monotherapy (respectively: -25.7 pg/ml, CI 95%, -31.6 to -19.7 pg/ml and -22.9 pg/ml, CI 95%, -28 to -17.3 pg/ml, p 0.002). Data at 270 days confirmed this trend (-37.8 pg/ml, CI 95%, -43.6 to -32.1 pg/ml vs -24.4 pg/ml, CI 95%, -30.3 to -18.4 pg/ml). The quality of life (QoL) score was investigated by the validated “Thyroid-related Patient-Reported Outcome” questionnaire (ThyPRO). ThyPRO composite score showed a greater improvement in the intervention group at 45 days (-14.6, CI 95%, -18.8 to -10.4), 180 (-9, CI 95%, -13.9 to -4.2) and 270 days (-14.3, CI 95%, -19.5 to -9.1) compared to MMI group (respectively, -5.2, CI 95%, -9.5 to -1; -5.4, CI 95%, -10.6 to -0.2 and -3.5, CI 95%, -9 to -2.1, p 0-6 months and 6-9 months <0.05). Our results suggest that reaching optimal Se and VitD levels increases the early efficacy of MMI treatment when Se and VitD levels are suboptimal. Frontiers Media S.A. 2022-06-15 /pmc/articles/PMC9240752/ /pubmed/35784564 http://dx.doi.org/10.3389/fendo.2022.886451 Text en Copyright © 2022 Gallo, Mortara, Veronesi, Cattaneo, Genoni, Gallazzi, Peruzzo, Lasalvia, Moretto, Bruno, Passi, Pini, Nauti, Lavizzari, Marinò, Lanzolla, Tanda, Bartalena and Piantanida https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Endocrinology
Gallo, Daniela
Mortara, Lorenzo
Veronesi, Giovanni
Cattaneo, Simona AM
Genoni, Angelo
Gallazzi, Matteo
Peruzzo, Carlo
Lasalvia, Paolo
Moretto, Paola
Bruno, Antonino
Passi, Alberto
Pini, Andrea
Nauti, Andrea
Lavizzari, Maria Antonietta
Marinò, Michele
Lanzolla, Giulia
Tanda, Maria Laura
Bartalena, Luigi
Piantanida, Eliana
Add-On Effect of Selenium and Vitamin D Combined Supplementation in Early Control of Graves’ Disease Hyperthyroidism During Methimazole Treatment
title Add-On Effect of Selenium and Vitamin D Combined Supplementation in Early Control of Graves’ Disease Hyperthyroidism During Methimazole Treatment
title_full Add-On Effect of Selenium and Vitamin D Combined Supplementation in Early Control of Graves’ Disease Hyperthyroidism During Methimazole Treatment
title_fullStr Add-On Effect of Selenium and Vitamin D Combined Supplementation in Early Control of Graves’ Disease Hyperthyroidism During Methimazole Treatment
title_full_unstemmed Add-On Effect of Selenium and Vitamin D Combined Supplementation in Early Control of Graves’ Disease Hyperthyroidism During Methimazole Treatment
title_short Add-On Effect of Selenium and Vitamin D Combined Supplementation in Early Control of Graves’ Disease Hyperthyroidism During Methimazole Treatment
title_sort add-on effect of selenium and vitamin d combined supplementation in early control of graves’ disease hyperthyroidism during methimazole treatment
topic Endocrinology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9240752/
https://www.ncbi.nlm.nih.gov/pubmed/35784564
http://dx.doi.org/10.3389/fendo.2022.886451
work_keys_str_mv AT gallodaniela addoneffectofseleniumandvitamindcombinedsupplementationinearlycontrolofgravesdiseasehyperthyroidismduringmethimazoletreatment
AT mortaralorenzo addoneffectofseleniumandvitamindcombinedsupplementationinearlycontrolofgravesdiseasehyperthyroidismduringmethimazoletreatment
AT veronesigiovanni addoneffectofseleniumandvitamindcombinedsupplementationinearlycontrolofgravesdiseasehyperthyroidismduringmethimazoletreatment
AT cattaneosimonaam addoneffectofseleniumandvitamindcombinedsupplementationinearlycontrolofgravesdiseasehyperthyroidismduringmethimazoletreatment
AT genoniangelo addoneffectofseleniumandvitamindcombinedsupplementationinearlycontrolofgravesdiseasehyperthyroidismduringmethimazoletreatment
AT gallazzimatteo addoneffectofseleniumandvitamindcombinedsupplementationinearlycontrolofgravesdiseasehyperthyroidismduringmethimazoletreatment
AT peruzzocarlo addoneffectofseleniumandvitamindcombinedsupplementationinearlycontrolofgravesdiseasehyperthyroidismduringmethimazoletreatment
AT lasalviapaolo addoneffectofseleniumandvitamindcombinedsupplementationinearlycontrolofgravesdiseasehyperthyroidismduringmethimazoletreatment
AT morettopaola addoneffectofseleniumandvitamindcombinedsupplementationinearlycontrolofgravesdiseasehyperthyroidismduringmethimazoletreatment
AT brunoantonino addoneffectofseleniumandvitamindcombinedsupplementationinearlycontrolofgravesdiseasehyperthyroidismduringmethimazoletreatment
AT passialberto addoneffectofseleniumandvitamindcombinedsupplementationinearlycontrolofgravesdiseasehyperthyroidismduringmethimazoletreatment
AT piniandrea addoneffectofseleniumandvitamindcombinedsupplementationinearlycontrolofgravesdiseasehyperthyroidismduringmethimazoletreatment
AT nautiandrea addoneffectofseleniumandvitamindcombinedsupplementationinearlycontrolofgravesdiseasehyperthyroidismduringmethimazoletreatment
AT lavizzarimariaantonietta addoneffectofseleniumandvitamindcombinedsupplementationinearlycontrolofgravesdiseasehyperthyroidismduringmethimazoletreatment
AT marinomichele addoneffectofseleniumandvitamindcombinedsupplementationinearlycontrolofgravesdiseasehyperthyroidismduringmethimazoletreatment
AT lanzollagiulia addoneffectofseleniumandvitamindcombinedsupplementationinearlycontrolofgravesdiseasehyperthyroidismduringmethimazoletreatment
AT tandamarialaura addoneffectofseleniumandvitamindcombinedsupplementationinearlycontrolofgravesdiseasehyperthyroidismduringmethimazoletreatment
AT bartalenaluigi addoneffectofseleniumandvitamindcombinedsupplementationinearlycontrolofgravesdiseasehyperthyroidismduringmethimazoletreatment
AT piantanidaeliana addoneffectofseleniumandvitamindcombinedsupplementationinearlycontrolofgravesdiseasehyperthyroidismduringmethimazoletreatment